The texture was pliant, the flavor tasted good, and there wasnt any weird aftertaste sinistral behind
(Tell me in the comments #ObesityMedicine #GLP1 #WeightManagement #FDAApproval #ClinicalPharmacy #MedicationAccess #PublicHealth #HealthEquity #ThePublicHealthPharmacist To view or add a comment, sign in The FDA has granted expedited approval to Eli Lilly's new weight-loss pill, orforglipron (Foundayo), marking it as the second daily oral GLP-1 medication for obesity
This underscores that weight loss pharmacology must be metabolically intelligent, not just calorically restrictive
doi:10.1177/193229681000400607 114
It always takes a while for a new drug to reach the general population
Effects of Liraglutide on Weight Loss, Fat Distribution, and -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes